Overview

Conditions acute myeloid leukemia, secondary acute myeloid leukemia, untreated adult acute myeloid leukemia
Treatments decitabine, selinexor, pharmacological study, laboratory biomarker analysis
Phase phase 1
Target XPO1
Sponsor Bhavana Bhatnagar
Collaborator Karyopharm Therapeutics, Inc
Start date March 2014
End date July 2017
Trial size 42 participants
Trial identifier NCT02093403, NCI-2014-00559, OSU-13182

Summary

This phase I trial studies the side effects and best dose of Selinexor when given together with decitabine in treating patients with acute myeloid leukemia that has returned after treatment (relapsed) or does not respond to treatment (refractory). Drugs used in chemotherapy, such as decitabine and Selinexor, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Recruiting in the following locations…

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10 and selinexor PO on days 11, 13, 18, 20, 25 and 27. Treatment repeats every 31 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive decitabine IV over 1 hour on days 1-5 and selinexor PO on days 6, 8, 13, 15, 20 and 22. Courses repeat every 31 days in the absence of disease progression or unacceptable toxicity.
decitabine 5-aza-dCyd
Given IV
selinexor CRM1 nuclear export inhibitor KPT-330
Given PO
pharmacological study pharmacological studies
Correlative studies
laboratory biomarker analysis
Correlative studies

Primary Outcomes

Measure
MTD defined as the dose where at most one patient experiences DLT with the next higher dose having at least 2 patients who experience DLT graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
time frame: 31 days
Incidence of severe (grade 3+) adverse events or toxicities assessed by NCI CTCAE version 4.03
time frame: Up to 3 years
Tolerability of the regimen defined by the number of patients who required dose modifications and/or dose delays
time frame: Up to 3 years
Proportion of patients who go off treatment due to adverse reactions
time frame: Up to 3 years

Secondary Outcomes

Measure
Overall response rate
time frame: Up to 3 years
Complete response rate
time frame: Up to 3 years
Change in expression of XPO1
time frame: Baseline to up to day 31 of course 1
Change in expression of genes associated with XPO1
time frame: Baseline to up to day 31 of course 1
Change in expression of miRs associated with XPO1
time frame: Baseline to up to day 31 of course 1
Change in expression of methylated signatures
time frame: Baseline to up to day 31 of course 1

Eligibility Criteria

Male or female participants at least 19 years old.

Inclusion Criteria: - Patients with relapsed or refractory AML - Newly diagnosed elderly AML patients (> 60 years) unfit for intensive chemotherapy with cytarabine and anthracyclines are also eligible to this trial given that no clinically beneficial therapy exists for these patients - Patients with secondary AML or therapy related disease (t‐AML) are eligible; patients who received decitabine or 5‐azacytidine as prior treatment for myelodysplastic syndrome (MDS) or AML remain eligible; however, none of these agents is permitted within 6 months of study entry - If the patient has co‐morbid medical illness, life expectancy attributed to this must be greater than 6 months - Eastern Cooperative Oncology Group (ECOG) performance status < 2 - Total bilirubin < 2.0 mg/dL - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 X institutional upper limit of normal - Creatinine < 2.0 mg/d - Glomerular filtration rate (GFR) > 50 mL/min - New York Heart Association (NYHA) congestive heart failure (CHF) class II or better - Female patients of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a female of child]bearing potential; acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal; for both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose - Ability to understand and willingness to sign the written informed consent document - Human immunodeficiency virus (HIV) infection without history of acquired immune deficiency syndrome (AIDS) and sufficiently high cluster of differentiation (CD)4 cells (> 400/mm^3) and low HIV viral loads (< 30,000 copies/ml plasma) not requiring anti‐HIV therapy are eligible - Patients must have recovered from the toxicity of prior therapy to less than grade 2 Exclusion Criteria: - Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study - Patients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollment - Patients with active central nervous system (CNS) malignancy; asymptomatic small lesions are not considered active; treated lesions may be considered inactive if they are stable for at least 3 months; patients with malignant cells in their cerebrospinal fluid (CSF) without CNS symptoms may be included - Patients with history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine that are not easily managed - Major surgery within 2 weeks before day 1 - Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose - Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus (HCV) ribonucleic acid (RNA) or HBsAg (hepatitis B virus [HBV] surface antigen) - Patients with significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea - History of seizures, movement disorders or cerebrovascular accident within the past 3 years prior to cycle 1 day 1 - Patients with macular degeneration, uncontrolled glaucoma, or markedly decreased visual acuity - Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure (New York Heart Association [NYHA] class III or IV), unstable angina pectoris, myocardial infarction within 6 months prior to enrollment, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities; prior to study entry, any electrocardiogram (ECG) abnormality at screening has to be documented by the investigator as not medically relevant - Patients with serious medical or psychiatric illness likely to interfere with participation in this clinical study - Pregnant women or women who are breastfeeding are excluded from this study; confirmation that the subject is not pregnant must be established by a negative serum beta‐human chorionic gonadotropin (beta‐hCG) pregnancy test result obtained during screening; pregnancy testing is not required for post‐menopausal or surgically sterilized women - Patients with advanced malignant solid tumors are excluded - Patients with renal failure (GFR < 50 mL/min) are excluded - Patients that in the opinion of the investigators are significantly below their ideal body weight

Additional Information

Official title Phase I Study of Decitabine (Dacogen) and Selinexor (KPT-330) in Acute Myeloid Leukemia
Principal investigator Bhavana Bhatnagar, DO
Description PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of Selinexor (KPT‐330) in combination with decitabine in patients with acute myeloid leukemia (AML). II. To define the specific toxicities, maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of this combination. III. To determine the Recommended Phase 2 Dose (RP2D) of this combination. SECONDARY OBJECTIVES: I. To determine the overall response rate (ORR). II. To determine the rate and duration of complete remission (CR) +/- hematological recovery of KPT‐330 plus decitabine in AML. III. To conduct pharmacodynamic studies by measuring the effect of this chemotherapy combination on the kinome, micronome and epigenome. OUTLINE: This is a dose-escalation study of selinexor. INDUCTION: Patients receive decitabine intravenously (IV) over 1 hour on days 1-10 and Selinexor orally (PO) on days 11, 13, 18, 20, 25 and 27. Treatment repeats every 31 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive decitabine IV over 1 hour on days 1-5 and Selinexor PO on days 6, 8, 13, 15, 20 and 22. Courses repeat every 31 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by Ohio State University Comprehensive Cancer Center.